(VIANEWS) – Simulations Plus (SLP), Virtu Financial (VIRT), First Busey Corporation (BUSE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Simulations Plus (SLP)
38.9% sales growth and 5.51% return on equity
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Earnings Per Share
As for profitability, Simulations Plus has a trailing twelve months EPS of $0.48.
PE Ratio
Simulations Plus has a trailing twelve months price to earnings ratio of 73.04. Meaning, the purchaser of the share is investing $73.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.51%.
Yearly Top and Bottom Value
Simulations Plus’s stock is valued at $35.06 at 01:22 EST, way below its 52-week high of $51.22 and above its 52-week low of $32.69.
Volume
Today’s last reported volume for Simulations Plus is 82793 which is 41.7% below its average volume of 142022.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 66.98M for the twelve trailing months.
2. Virtu Financial (VIRT)
35.1% sales growth and 24.4% return on equity
Virtu Financial, Inc., together with its subsidiaries, provides market making and liquidity services through its proprietary, multi-asset, and multi-currency technology platform to the financial markets worldwide. The company's Market Making segment principally consists of market making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Its Execution Services segment comprises agency-based trading and trading venues, which offer execution services in equities, ETFs, futures, fixed income, currencies, and commodities to institutions, banks, and broker dealers. Virtu Financial, Inc. was founded in 2008 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Virtu Financial has a trailing twelve months EPS of $1.99.
PE Ratio
Virtu Financial has a trailing twelve months price to earnings ratio of 15.12. Meaning, the purchaser of the share is investing $15.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.4%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 42.3%, now sitting on 1.83B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 55.6% and 177.8%, respectively.
Volume
Today’s last reported volume for Virtu Financial is 611700 which is 62.62% below its average volume of 1636750.
3. First Busey Corporation (BUSE)
29% sales growth and 8.68% return on equity
First Busey Corporation operates as the bank holding company for Busey Bank that provides retail and commercial banking products and services to individual, corporate, institutional, and governmental customers in the United States. The company operates through three segments: Banking, FirsTech, and Wealth Management. It offers banking services to individual and corporate customers. The company also provides asset management, investment, brokerage, fiduciary, philanthropic advisory, tax preparation, and farm management services. Further, it offers payment technology solutions through its payment platform, such as walk-in payment processing for customers at retail pay agents; online bill payment solutions; customer service payments accepted over the telephone; mobile bill pay; direct debit services; electronic concentration of payments delivered to automated clearing house network; money management and credit card networks; and lockbox remittance processing to make payments by mail, as well as provides tools related to billing, reconciliation, bill reminders, and treasury services. The company has 46 banking centers in Illinois; 8 in Missouri; 3 in southwest Florida; and 1 in Indianapolis, Indiana. First Busey Corporation was founded in 1868 and is headquartered in Champaign, Illinois.
Earnings Per Share
As for profitability, First Busey Corporation has a trailing twelve months EPS of $1.94.
PE Ratio
First Busey Corporation has a trailing twelve months price to earnings ratio of 13.87. Meaning, the purchaser of the share is investing $13.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.68%.
Sales Growth
First Busey Corporation’s sales growth is 10.2% for the current quarter and 29% for the next.
Volume
Today’s last reported volume for First Busey Corporation is 673649 which is 157.59% above its average volume of 261519.
4. Palomar Holdings (PLMR)
21.9% sales growth and 20.38% return on equity
Palomar Holdings, Inc., an insurance holding company, provides specialty property insurance to residential and commercial customers. The company offers personal and commercial specialty property insurance products, including residential and commercial earthquake, commercial all risk, specialty homeowners, inland marine, Hawaii hurricane, and residential flood, as well as other products, such as assumed reinsurance, commercial flood, real estate error and omission, and real estate investor products. It markets and distributes its products through retail agents, wholesale brokers, program administrators, and carrier partnerships. The company was formerly known as GC Palomar Holdings. Palomar Holdings, Inc. was incorporated in 2013 and is headquartered in La Jolla, California.
Earnings Per Share
As for profitability, Palomar Holdings has a trailing twelve months EPS of $3.8.
PE Ratio
Palomar Holdings has a trailing twelve months price to earnings ratio of 24.82. Meaning, the purchaser of the share is investing $24.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.38%.
Sales Growth
Palomar Holdings’s sales growth for the next quarter is 21.9%.
5. Badger Meter (BMI)
12.7% sales growth and 21.73% return on equity
Badger Meter, Inc. manufactures and markets flow measurement, quality, control, and communication solutions in the United States, Asia, Canada, Europe, Mexico, the Middle East, and internationally. It offers mechanical or static water meters, and related radio and software technologies and services to municipal water utilities. The company also provides flow instrumentation products, including meters, valves, and other sensing instruments to measure and control fluids going through a pipe or pipeline, including water, air, steam, oil, and other liquids and gases to original equipment manufacturers as the primary flow measurement device within a product or system, as well as through manufacturers' representatives. Its flow instrumentation products are used in water/wastewater, heating, ventilating and air conditioning, and corporate sustainability markets. In addition, the company offers ORION Migratable for automatic meter reading; ORION (SE) for traditional fixed network applications; and ORION Cellular for infrastructure-free fixed network meter reading solution, as well as BEACON advanced metering analytics, a secure cloud-hosted software suite that establishes alerts for specific conditions and allows consumer engagement tools that permit end water customers to view and manage their water usage activity. It also serves water utilities, industrial, and other industries. The company sells its products directly, as well as through resellers and representatives. Badger Meter, Inc. was founded in 1905 and is headquartered in Milwaukee, Wisconsin.
Earnings Per Share
As for profitability, Badger Meter has a trailing twelve months EPS of $3.84.
PE Ratio
Badger Meter has a trailing twelve months price to earnings ratio of 52.85. Meaning, the purchaser of the share is investing $52.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.73%.
Moving Average
Badger Meter’s value is above its 50-day moving average of $194.17 and way above its 200-day moving average of $170.33.
Previous days news about Badger Meter(BMI)
- According to Zacks on Friday, 6 September, "Some better-ranked stocks worth consideration in the broader technology space are Badger Meter (BMI Quick QuoteBMI – Free Report) , Adobe (ADBE Quick QuoteADBE – Free Report) and ANSYS (ANSS Quick QuoteANSS – Free Report) , each currently carrying a Zacks Rank #2 (Buy). "
- According to Zacks on Friday, 6 September, "Some better-ranked stocks in the broader technology sector are AudioEye (AEYE Quick QuoteAEYE – Free Report) , Aspen Technology (AZPN Quick QuoteAZPN – Free Report) and Badger Meter (BMI Quick QuoteBMI – Free Report) . ", "AudioEye and Aspen Technology currently sports Zacks Rank #1 (Strong Buy) at present whereas Badger Meter carries a Zacks Rank #2 (Buy). "
6. Kamada Ltd. (KMDA)
9.5% sales growth and 7.05% return on equity
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.27.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 21.3. Meaning, the purchaser of the share is investing $21.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.05%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 16.7% and a drop 33.3% for the next.
Sales Growth
Kamada Ltd.’s sales growth is 7.9% for the current quarter and 9.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.4%, now sitting on 154.57M for the twelve trailing months.
7. Criteo (CRTO)
6.6% sales growth and 9.95% return on equity
Criteo S.A., a technology company, provides marketing and monetization services on the open Internet in North and South America, Europe, the Middle East, Africa, and the Asia-Pacific. The company's Criteo Shopper Graph, which derives clients' proprietary commerce data, such as transaction activity on their digital properties. It also offers Criteo AI Engine solutions, including lookalike finder, recommendation, and predictive bidding algorithms; recommendation algorithms, dynamic creative optimization+, sponsored product placement algorithms, and other product placement algorithms. The company's technology comprises data synchronization, storage, and analysis of distributed computing infrastructure in various geographies, as well as fast data collection and retrieval using multi-layered caching infrastructure; and experimentation platform, an offline/online testing platform to enhance the capabilities and effectiveness of prediction models. In addition, it provides Criteo Marketing Solutions that allow commerce companies to address various marketing goals by engaging their consumers with personalized ads across the web, mobile, and offline store environments; and Criteo Retail Media solutions, which allows retailers to generate advertising revenues from consumer brands, and/or to drive sales for themselves, by monetizing their data and audiences through personalized ads, either on their own digital property or on the open Internet. Further, the company offers real-time advertising technology and trading infrastructure, delivering advanced media buying, selling, and packaging capabilities for media owners, agencies, performance advertisers, and third-party AdTech platforms. It serves companies in digital retail, travel, and classifieds sectors. Criteo S.A. was incorporated in 2005 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, Criteo has a trailing twelve months EPS of $0.88.
PE Ratio
Criteo has a trailing twelve months price to earnings ratio of 39.16. Meaning, the purchaser of the share is investing $39.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.95%.
Volume
Today’s last reported volume for Criteo is 125074 which is 49.58% below its average volume of 248085.
Yearly Top and Bottom Value
Criteo’s stock is valued at $34.46 at 01:22 EST, way under its 52-week high of $49.93 and way higher than its 52-week low of $22.10.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.5%, now sitting on 1.96B for the twelve trailing months.
8. PulteGroup (PHM)
5.9% sales growth and 26.97% return on equity
PulteGroup, Inc., through its subsidiaries, primarily engages in the homebuilding business in the United States. It acquires and develops land primarily for residential purposes; and constructs housing on such land. The company also offers various home designs, including single-family detached, townhomes, condominiums, and duplexes under the Centex, Pulte Homes, Del Webb, DiVosta Homes, American West, and John Wieland Homes and Neighborhoods brand names. As of December 31, 2022, it controlled 211,112 lots, of which 108,848 were owned and 102,264 were under land option agreements. In addition, the company arranges financing through the origination of mortgage loans primarily for homebuyers; sells the servicing rights for the originated loans; and provides title insurance policies, and examination and closing services to homebuyers. The company was founded in 1950 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, PulteGroup has a trailing twelve months EPS of $13.1.
PE Ratio
PulteGroup has a trailing twelve months price to earnings ratio of 10.04. Meaning, the purchaser of the share is investing $10.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.97%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 18, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.6%.
Previous days news about PulteGroup(PHM)
- After 27% YTD jump, will rate cuts push pultegroup stock to new highs?. According to Zacks on Friday, 6 September, "Overall, PulteGroup reiterated the outlook of 5% to 10% longer-term annual growth for the business. ", "Investors should strongly consider buying PulteGroup stock now, given its potential of emerging as a strong player despite the ongoing housing market volatility by facilitating various strategic initiatives, including a balanced operating model, offering an appealing mortgage rate buydown program and a favorable pricing structure. "
